Related Experiment Video
Updated: Apr 19, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic
Kathy Zhang1, Melissa L Geddie, Neeraj Kohli
1a Merrimack Pharmaceuticals, Inc. ; Cambridge , MA USA.
Abstract:
Antibody-targeted nanoparticles have the potential to significantly increase the therapeutic index of cytotoxic anti-cancer therapies by directing them to tumor cells. Using antibodies or their fragments requires careful engineering because multiple parameters, including affinity, internalization rate and stability, all need to be optimized. Here, we present a case study of the iterative engineering of a single chain variable fragment (scFv) for use as a targeting arm of a liposomal cytotoxic nanoparticle. We describe the effect of the orientation of variable domains, the length and composition of the interdomain protein linker that connects VH and VL, and stabilizing mutations in both the framework and complementarity-determining regions (CDRs) on the molecular properties of the scFv. We show that variable domain orientation can alter cross-reactivity to murine antigen while maintaining affinity to the human antigen. We demonstrate that tyrosine residues in the CDRs make diverse contributions to the binding affinity and biophysical properties, and that replacement of non-essential tyrosines can improve the stability and bioactivity of the scFv. Our studies demonstrate that a comprehensive engineering strategy may be required to identify a scFv with optimal characteristics for nanoparticle targeting.
Insights
Engineering antibody fragments (scFvs) for targeted cancer therapy nanoparticles requires optimizing affinity, stability, and internalization. Iterative design of scFvs enhances their suitability for antibody-targeted nanoparticle drug delivery.
Area of Science:
- Biotechnology
- Nanomedicine
- Immunology
Background:
- Antibody-targeted nanoparticles enhance anti-cancer therapy by directing cytotoxic agents to tumor cells.
- Optimizing antibody fragments (scFvs) for nanoparticle applications involves complex engineering of affinity, stability, and internalization rates.
Purpose of the Study:
- To present a case study on the iterative engineering of a single-chain variable fragment (scFv) for nanoparticle targeting.
- To investigate the impact of variable domain orientation, linker properties, and stabilizing mutations on scFv performance.
Main Methods:
- Iterative engineering of an scFv targeting arm for liposomal nanoparticles.
- Systematic modification of variable domain orientation, interdomain linker length/composition, and framework/CDR mutations.
- Assessment of molecular properties, including antigen affinity, cross-reactivity, stability, and bioactivity.
Main Results:
- Variable domain orientation influences cross-reactivity to murine antigens while preserving human antigen affinity.
- Tyrosine residues in complementarity-determining regions (CDRs) critically affect binding affinity and biophysical properties.
- Replacing non-essential tyrosines in CDRs can enhance scFv stability and bioactivity.
Conclusions:
- Comprehensive engineering strategies are essential for developing optimal scFvs for antibody-targeted nanoparticle delivery.
- Fine-tuning scFv properties through domain orientation, linker design, and targeted mutations improves their therapeutic potential.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014